Hematological Oncology最新文献

{"title":"Strategies for overcoming resistance to Bruton's tyrosine kinase inhibitor zanubrutinib","authors":"Hana Dostálová,&nbsp;Vladimír Kryštof","doi":"10.1002/hon.3294","DOIUrl":"10.1002/hon.3294","url":null,"abstract":"<p>Bruton's tyrosine kinase (BTK) inhibitors have revolutionized the treatment of B-cell malignancies. They target BTK, a key effector in the B-cell receptor (BCR) signaling pathway, crucial for B-cell survival and proliferation. The first-in-class irreversible BTK inhibitor, ibrutinib, was approved for various B-cell malignancies but has limitations due to off-target effects. Second-generation inhibitors, such as acalabrutinib and zanubrutinib, offer improved selectivity and reduced side effects. However, resistance to BTK inhibitors, driven by BTK mutations, remains a challenge. Combinatorial therapies with PI3K inhibitors, immune checkpoint inhibitors, BH3 mimetics, and anti-CD20 antibodies show promise in overcoming resistance. Noncovalent BTK inhibitors and proteolysis-targeting chimeras (PROTACs) are emerging strategies with potential to combat resistance. Overall, advancements in BTK-targeted therapies provide hope for improved outcomes in patients with B-cell malignancies and a promising avenue to address drug resistance. Further research is needed to optimize combination therapies and identify optimal treatment regimens.</p>","PeriodicalId":12882,"journal":{"name":"Hematological Oncology","volume":"42 4","pages":""},"PeriodicalIF":3.3,"publicationDate":"2024-06-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1002/hon.3294","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141283540","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"A real-life study of daratumumab combinations in newly diagnosed patients with light chain (AL) amyloidosis","authors":"Claudia Bellofiore,&nbsp;Pietro Benvenuti,&nbsp;Roberto Mina,&nbsp;Marco Basset,&nbsp;Andrea Foli,&nbsp;Martina Nanci,&nbsp;Mario Nuvolone,&nbsp;Gianluigi Guida,&nbsp;Andrea Attanasio,&nbsp;Roberta Mussinelli,&nbsp;Silvia Mangiacavalli,&nbsp;Claudio Salvatore Cartia,&nbsp;Valeria Masoni,&nbsp;Michele Palumbo,&nbsp;Lorenzo Cani,&nbsp;Stefania Oliva,&nbsp;Ugo Consoli,&nbsp;Concetta Conticello,&nbsp;Francesco Di Raimondo,&nbsp;Luca Arcaini,&nbsp;Sara Bringhen,&nbsp;Giampaolo Merlini,&nbsp;Giovanni Palladini,&nbsp;Paolo Milani","doi":"10.1002/hon.3289","DOIUrl":"10.1002/hon.3289","url":null,"abstract":"<p>Daratumumab-based regimens are the new standard of care for newly diagnosed patients with AL amyloidosis based on the results of the ANDROMEDA study. However, real-world data on daratumumab efficacy in upfront therapy in unselected patients are scanty. In the framework of a prospective observational study, we investigated the efficacy and safety of daratumumab in 88 newly diagnosed patients, including subjects with IIIb cardiac stage (26%) or myeloma defining events (29%). Daratumumab was administered with bortezomib in 50 (56%) patients, lenalidomide in 31 (35%), and monotherapy in 7 (8%). The rate of serious adverse events was low (16%). The overall hematologic response rate was 75% with 52 (59%) patients attaining at least a very good partial response (VGPR) at six months. Amongst patients evaluable for organ response, the rate of cardiac and renal responses at 6 months was 31% and 21%, respectively. Comparing stage IIIb patients with the remaining ones, the rate of profound hematologic response was not significantly different (≥VGPR 57% vs. 59%, <i>p</i> 0.955) likewise the rate of cardiac (33% vs. 30%, <i>p</i> 0.340) and renal (40% vs. 16%, <i>p</i> 0.908) responses. Daratumumab-based regimens demonstrated to be safe and effective in treatment-naïve AL amyloidosis even in advanced stage disease.</p>","PeriodicalId":12882,"journal":{"name":"Hematological Oncology","volume":"42 4","pages":""},"PeriodicalIF":3.3,"publicationDate":"2024-06-02","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141185878","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Elotuzumab plus pomalidomide and dexamethasone in relapsed/refractory multiple myeloma: Extended follow-up of a multicenter, retrospective real-world experience with 321 cases outside of controlled clinical trials","authors":"Enrica Antonia Martino,&nbsp;Salvatore Palmieri,&nbsp;Monica Galli,&nbsp;Daniele Derudas,&nbsp;Roberto Mina,&nbsp;Roberta Della Pepa,&nbsp;Renato Zambello,&nbsp;Ernesto Vigna,&nbsp;Antonella Bruzzese,&nbsp;Silvia Mangiacavalli,&nbsp;Elena Zamagni,&nbsp;Catello Califano,&nbsp;Maurizio Musso,&nbsp;Concetta Conticello,&nbsp;Claudio Cerchione,&nbsp;Giuseppe Mele,&nbsp;Nicola Di Renzo,&nbsp;Massimo Offidani,&nbsp;Giuseppe Tarantini,&nbsp;Gloria Margiotta Casaluci,&nbsp;Angela Rago,&nbsp;Roberto Ria,&nbsp;Giuseppina Uccello,&nbsp;Gregorio Barilà,&nbsp;Gaetano Palumbo,&nbsp;Loredana Pettine,&nbsp;Iolanda Donatella Vincelli,&nbsp;Marino Brunori,&nbsp;Fabrizio Accardi,&nbsp;Valeria Amico,&nbsp;Angela Amendola,&nbsp;Raffaele Fontana,&nbsp;Velia Bongarzoni,&nbsp;Bernardo Rossini,&nbsp;Emilia Cotzia,&nbsp;Alessandro Gozzetti,&nbsp;Rita Rizzi,&nbsp;Nicola Sgherza,&nbsp;Giovanni Reddiconto,&nbsp;Antonio Maroccia,&nbsp;Luca Franceschini,&nbsp;Giuseppe Bertuglia,&nbsp;Davide Nappi,&nbsp;Emiliano Barbieri,&nbsp;Barbara Gamberi,&nbsp;Maria Teresa Petrucci,&nbsp;Francesco Di Raimondo,&nbsp;Antonino Neri,&nbsp;Fortunato Morabito,&nbsp;Pellegrino Musto,&nbsp;Massimo Gentile","doi":"10.1002/hon.3290","DOIUrl":"10.1002/hon.3290","url":null,"abstract":"<p>The ELOQUENT-3 trial demonstrated the superiority of the combination of elotuzumab, pomalidomide, and dexamethasone (EloPd) in terms of efficacy and safety, compared to Pd in relapsed/refractory multiple myeloma (RRMM), who had received at least two prior therapies, including lenalidomide and a proteasome inhibitor. The present study is an 18-month follow-up update of a previously published Italian real-life RRMM cohort of patients treated with EloPd. This revised analysis entered 319 RRMM patients accrued in 41 Italian centers. After a median follow-up of 17.7 months, 213 patients (66.4%) experienced disease progression or died. Median progression-free survival (PFS) and overall survival (OS) were 7.5 and 19.2 months, respectively. The updated multivariate analysis showed a significant reduction of PFS benefit magnitude both in advanced International Staging System (ISS) (II and III) stages and previous exposure to daratumumab cases. Instead, advanced ISS (II and III) stages and more than 2 previous lines of therapy maintained an independent prognostic impact on OS. Major adverse events included grade three-fourths neutropenia (24.9%), anemia (13.4%), lymphocytopenia (15.5%), and thrombocytopenia (10.7%), while infection rates and pneumonia were 19.3% and 8.7%, respectively. A slight increase in the incidence of neutropenia and lymphocytopenia was registered with longer follow-up. In conclusion, our real-world study still confirms that EloPd is a safe and possible therapeutic choice for RRMM. Nevertheless, novel strategies are desirable for those patients exposed to daratumumab.</p>","PeriodicalId":12882,"journal":{"name":"Hematological Oncology","volume":"42 4","pages":""},"PeriodicalIF":3.3,"publicationDate":"2024-05-31","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141179587","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Metabolic pathway-based subtyping reveals distinct microenvironmental states associated with diffuse large B-cell lymphoma outcomes","authors":"Xiaohui Wang,&nbsp;Hengqi Liu,&nbsp;Yue Fei,&nbsp;Zheng Song,&nbsp;Xiangrui Meng,&nbsp;Jingwei Yu,&nbsp;Xia Liu,&nbsp;Lanfang Li,&nbsp;Lihua Qiu,&nbsp;Zhengzi Qian,&nbsp;Shiyong Zhou,&nbsp;Xianhuo Wang,&nbsp;Huilai Zhang","doi":"10.1002/hon.3279","DOIUrl":"10.1002/hon.3279","url":null,"abstract":"<p>Diffuse large B-cell lymphoma (DLBCL) is a biologically and clinically heterogeneous disease that requires personalized clinical treatment. Assigning patients to different risk categories and cytogenetic abnormality and genetic mutation groups has been widely applied for prognostic stratification of DLBCL. Increasing evidence has demonstrated that dysregulated metabolic processes contribute to the initiation and progression of DLBCL. Metabolic competition within the tumor microenvironment is also known to influence immune cell metabolism. However, metabolism- and immune-related stratification has not been established. Here, 1660 genes involved in 84 metabolic pathways were selected and tested to establish metabolic clusters (MECs) of DLBCL. MECs established based on independent lymphoma datasets distinguished different survival outcomes. The CIBERSORT algorithm and EcoTyper were applied to quantify the relative abundance of immune cell types and identify variation in cell states for 13 lineages comprising the tumor micro environment among different MECs, respectively. Functional characterization showed that MECs were an indicator of the immune microenvironment and correlated with distinctive mutational characteristics and oncogenic signaling pathways. The novel immune-related MECs exhibited promising clinical prognostic value and potential for informing DLBCL treatment decisions.</p>","PeriodicalId":12882,"journal":{"name":"Hematological Oncology","volume":"42 4","pages":""},"PeriodicalIF":3.3,"publicationDate":"2024-05-31","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141179607","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"FLT3-ITD regulation of the endoplasmic reticulum functions in acute myeloid leukemia","authors":"María Turos-Cabal,&nbsp;Ana M. Sánchez-Sánchez,&nbsp;Noelia Puente-Moncada,&nbsp;Federico Herrera,&nbsp;Isaac Antolin,&nbsp;Carmen Rodríguez,&nbsp;Vanesa Martín","doi":"10.1002/hon.3281","DOIUrl":"10.1002/hon.3281","url":null,"abstract":"<p>The FLT3-ITD mutation represents the most frequent genetic alteration in newly diagnosed acute myeloid leukemia (AML) patient and is associated with poor prognosis. Mutation result in the retention of a constitutively active form of this receptor in the endoplasmic reticulum (ER) and the subsequent modification of its downstream effectors. Here, we assessed the impact of such retention on ER homeostasis and found that mutant cells present lower levels of ER stress due to the overexpression of ERO1α, one of the main proteins of the protein folding machinery at the ER. Overexpression of ERO1α resulted essential for ITD mutant cells survival and chemoresistance and also played a crucial role in shaping the type of glucose metabolism in AML cells, being the mitochondrial pathway the predominant one in those with a higher ER stress (non-mutated cells) and the glycolytic pathway the predominant one in those with lower ER stress (mutated cells). Our data indicate that FLT3 mutational status dictates the route for glucose metabolism in an ERO1α depending on manner and this provides a survival advantage to tumors carrying these ITD mutations.</p>","PeriodicalId":12882,"journal":{"name":"Hematological Oncology","volume":"42 3","pages":""},"PeriodicalIF":3.3,"publicationDate":"2024-05-22","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1002/hon.3281","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141075637","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Real-world data on diagnostics, treatment and outcomes of patients with hairy cell leukemia: The HCL-CLLEAR study","authors":"Anna Panovská,&nbsp;Pavel Žák,&nbsp;Tereza Jurková,&nbsp;Tomáš Arpáš,&nbsp;Yvona Brychtová,&nbsp;Alžběta Vašíková,&nbsp;Viera Hrabčáková,&nbsp;Adéla Prchlíková,&nbsp;Martina Filipová,&nbsp;Michael Doubek","doi":"10.1002/hon.3280","DOIUrl":"10.1002/hon.3280","url":null,"abstract":"<p>Hairy cell leukemia (HCL) and HCL-like disorders have to be distinguished because of their different biology and treatment response. Thus, we conducted a retrospective study on patients with HCL and hairy cell leukemia variant (HCLv) to assess diagnostic algorithms and treatment outcomes in a real-world setting. We analyzed 225 HCL and 26 HCLv patients with median follow-up of 67.9 months (HCL) and 20.1 months (HCLv). Median age at diagnosis was 56.2 (HCL) and 69.5 years (HCLv), male predominance was observed in both groups (76.0% vs. 73.1%). Diagnostics was mostly based on morphological evidence of hairy cells in the peripheral blood and bone marrow. At diagnosis, <i>BRAF</i> <i>V6</i>00E mutation was detected in 94.7% of examined HCL patients and in no HCLv patient. Front-line treatment was indicated in 205 (91.1%) HCL and 18 (69.2%) HCLv patients. The majority of HCL patients were administered a cladribine-based regimen (91.2%). Overall response rate (ORR) was higher in cladribine-treated patients compared to those given other treatments (97.7% vs. 81.3%), the same applied with achieving Complete remission (CR) (91.2% vs. 62.5%). HCLv treatment was heterogeneous, but cladribine remained the most frequent option (44.4%) with ORR 81.3% and CR rates 43.8%. Second-line treatment was indicated in 52 HCL and 8 HCLv patients, 25.4% and 44.4% of those treated in first-line. In the whole HCL group, median time to next treatment (TTNT) was not reached and 10-year TTNT was estimated at 74.1%. HCLv patients who underwent first-line treatment had a median TTNT of 56 months. The median overall survival (OS) in HCL patients was not reached compared to HCLv with a median OS of 9.5 years. These data confirm an excellent prognosis for HCL patients treated with cladribine-based therapy. On the contrary, HCLv with its aggressive behavior represents a group of patients in whom novel treatment approaches are needed.</p>","PeriodicalId":12882,"journal":{"name":"Hematological Oncology","volume":"42 3","pages":""},"PeriodicalIF":3.3,"publicationDate":"2024-05-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1002/hon.3280","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140916152","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Prognostic relevance of circulating lymphoma cells at diagnosis in newly diagnosed follicular lymphoma patients","authors":"Kaitlin Annunzio,&nbsp;Subodh Bhatta,&nbsp;Walter Hanel,&nbsp;Qiuhong Zhao,&nbsp;Mackenzie Owen,&nbsp;Havi Rosen,&nbsp;Timothy J. Voorhees,&nbsp;David A. Bond,&nbsp;Yazeed Sawalha,&nbsp;Audrey M. Sigmund,&nbsp;Lapo Alinari,&nbsp;Robert A. Baiocchi,&nbsp;Kami J. Maddocks,&nbsp;Daniel Jones,&nbsp;Beth Christian,&nbsp;Narendranath Epperla","doi":"10.1002/hon.3278","DOIUrl":"10.1002/hon.3278","url":null,"abstract":"<p>Follicular lymphoma (FL) is the most common indolent B-cell non-Hodgkin lymphoma. Circulating lymphoma (CL) cells can be seen at diagnosis in some FL patients, however, previous studies evaluating this have shown mixed results. Therefore, we sought to evaluate the impact of CL at diagnosis on outcomes in patients with newly diagnosed FL using data from a single center. Patients were divided into CL+ and CL− based on immunophenotyping via peripheral blood (PB) flow cytometry. CL was defined as detectable clonally restricted B-cells that matched the actual or expected B-cell immunophenotype of FL. The primary endpoint was progression-free survival (PFS) after first-line treatment and secondary endpoints included overall response rate (ORR), overall survival (OS), diagnosis to treatment interval (DTI), progression of disease within 2 years of diagnosis (POD24), and cumulative incidence of transformation between the two groups. Among the 541 patients with FL, 204 had PB flow cytometry performed at diagnosis, and after excluding patients not meeting the eligibility criteria, 147 cases remained with 24 (16%) CL+ at diagnosis. Patients in the CL+ group were younger (53 vs. 58 years, <i>p</i> = 0.02), had more extranodal involvement (83% vs. 44%, <i>p</i> &lt; 0.01), follicular lymphoma international prognostic index 3–5 (55% vs. 31%, <i>p</i> = 0.01), and a higher proportion received first-line immunochemotherapy (75% vs. 43%, <i>p</i> = 0.01) compared to the CL−group. The median PFS was not significantly different between CL+ (6.27 years, 95% CI = 3.61-NR) and CL− (6.61 years, 95% CI = 5.10–9.82) cohorts regardless of the first-line treatment or level of absolute PB CL cells. There was no significant difference in ORR, median OS, DTI, POD24, and cumulative incidence of transformation between the two groups. In our study, we found that the presence of CL cells at diagnosis in FL in the contemporary era did not impact outcomes and survival.</p>","PeriodicalId":12882,"journal":{"name":"Hematological Oncology","volume":"42 3","pages":""},"PeriodicalIF":3.3,"publicationDate":"2024-05-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140897880","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"A phase 3b study of venetoclax and azacitidine or decitabine in an outpatient setting in patients with acute myeloid leukemia","authors":"Sudhir Manda,&nbsp;Bertrand M. Anz III,&nbsp;Christopher Benton,&nbsp;E. Randolph Broun,&nbsp;Habte A. Yimer,&nbsp;John S. Renshaw,&nbsp;George Geils Jr,&nbsp;Jesus Berdeja,&nbsp;Jose Cruz,&nbsp;Jason M. Melear,&nbsp;Suzanne Fanning,&nbsp;Luke Fletcher,&nbsp;Yukun Li,&nbsp;Yinghui Duan,&nbsp;Michael E. Werner,&nbsp;Jalaja Potluri,&nbsp;Madhavi V. Pai,&nbsp;William B. Donnellan","doi":"10.1002/hon.3274","DOIUrl":"https://doi.org/10.1002/hon.3274","url":null,"abstract":"<div>\u0000 \u0000 \u0000 <section>\u0000 \u0000 <p>Venetoclax, a highly selective BCL-2 inhibitor, combined with hypomethylating agents (HMAs) azacitidine or decitabine, is approved for the treatment of newly diagnosed acute myeloid leukemia (ND AML) in patients who are ineligible to receive intensive chemotherapy. Previous clinical studies initiated venetoclax plus HMA in an inpatient setting owing to concerns of tumor lysis syndrome (TLS). This study (NCT03941964) evaluated the efficacy and safety of venetoclax plus HMA in a United States community–based outpatient setting in patients with ND AML (<i>N</i> = 60) who were treatment naïve for AML, ineligible to receive intensive chemotherapy, had no evidence of spontaneous TLS at screening, and were deemed as appropriate candidates for outpatient initiation of venetoclax plus HMA by the investigator. Patients received venetoclax in combination with azacitidine (75 mg/m²) or decitabine (20 mg/m²) for up to 6 cycles during the study. With a median time on study of 18.3 weeks, the best response rate of composite complete remission was 66.7%, and the overall post-baseline red blood cell (RBC) and platelet transfusion independence rate was 55.0%, consistent with results of studies in which treatment was initiated in an inpatient setting. Key adverse events included nausea, anemia, thrombocytopenia, neutropenia, and white blood cell count decrease of any grade (≥50% of patients). The observed safety profile was generally consistent with that of venetoclax plus HMA observed in inpatient AML studies. With close monitoring, 2 cases of TLS were identified, appropriately managed, and the patients were able to continue study treatment.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Clinical Trials Registration</h3>\u0000 \u0000 <p>This study is registered at ClinicalTrials.gov. The registration identification number is NCT03941964.</p>\u0000 </section>\u0000 </div>","PeriodicalId":12882,"journal":{"name":"Hematological Oncology","volume":"42 3","pages":""},"PeriodicalIF":3.3,"publicationDate":"2024-05-06","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140844787","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Comparison between indolent systemic mastocytosis and clonal mast cell disease not meeting WHO diagnostic criteria: A nationwide multicenter retrospective analysis","authors":"Mariarita Sciumè,&nbsp;Fabio Serpenti,&nbsp;Roberta Zanotti,&nbsp;Patrizia Bonadonna,&nbsp;Ilaria Tanasi,&nbsp;Lara Crosera,&nbsp;Chiara Elena,&nbsp;Francesco Mannelli,&nbsp;Francesca Crupi,&nbsp;Cristina Papayannidis,&nbsp;Chiara Sartor,&nbsp;Simona Soverini,&nbsp;Michela Rondoni,&nbsp;Cristina Eller-Vainicher,&nbsp;Valerio Pravettoni,&nbsp;Federica Rivolta,&nbsp;Silvia Alberti Violetti,&nbsp;Giorgio Alberto Croci,&nbsp;Anna Chiara Migliorini,&nbsp;Niccolò Bolli,&nbsp;Diana Giannarelli,&nbsp;Federica Irene Grifoni","doi":"10.1002/hon.3277","DOIUrl":"https://doi.org/10.1002/hon.3277","url":null,"abstract":"","PeriodicalId":12882,"journal":{"name":"Hematological Oncology","volume":"42 3","pages":""},"PeriodicalIF":3.3,"publicationDate":"2024-04-29","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140808189","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Retraction","authors":"","doi":"10.1002/hon.3276","DOIUrl":"https://doi.org/10.1002/hon.3276","url":null,"abstract":"<p>Retraction: “Liposomal-encapsulated doxorubicin supercharge-containing front-line treatment improves response rates in primary mediastinal large B-cell lymphoma and mediastinal gray zone lymphoma” by Picardi, M., Giordano, C., Pugliese, N., Mascolo, M., Varricchio, S., Troncone, G., Vigliar, E., Bellavicine, C., Lamagna, M., Lisi, D., Vincenzi, A. and Pane, F., <i>Hematol Oncol.</i>, 2024; 42: e3247. https://doi.org/10.1002/hon.3247.</p><p>The above article from <i>Hematological Oncology</i>, published online on 24 January 2024 in Wiley Online Library (wileyonlinelibrary.com), has been retracted by agreement between the journal's editor-in-chief, Francesco Bertoni, the authors, and John Wiley &amp; Sons Ltd. This action has been agreed due to an error at the publishers which caused this duplicate of another article to be published. The correct version of the article, first published online on 21 December 2023, is to be found at: “Liposomal-encapsulated doxorubicin supercharge-containing front-line treatment improves response rates in primary mediastinal large B-cell lymphoma and mediastinal gray zone lymphoma” by Picardi, M., Giordano, C., Pugliese, N., Mascolo, M., Varricchio, S., Troncone, G., Vigliar, E., Bellavicine, C., Lamagna, M., Lisi, D., Vincenzi, A. and Pane, F., <i>Hematol Oncol.</i>, 2024; 42: e3242. https://doi.org/10.1002/hon.3242.</p>","PeriodicalId":12882,"journal":{"name":"Hematological Oncology","volume":"42 3","pages":""},"PeriodicalIF":3.3,"publicationDate":"2024-04-29","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1002/hon.3276","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140814205","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}